Lantus Cost in New Hampshire 2026: Prices, Medicaid, Savings Programs

What Lantus Actually Costs in New Hampshire Right Now

The average cash-pay price for Lantus across New Hampshire retail pharmacies sits at roughly $35 per month in 2026. That figure represents a steep drop from Sanofi's manufacturer list price of $340 per month, driven by pharmacy discount programs, competitive pressure from biosimilars, and Sanofi's own pricing commitments.

The gap between list price and what patients actually pay has never been wider. Sanofi cut its U.S. list price for Lantus by 78% in 2024, following public pressure and federal attention to insulin affordability [1]. Before that cut, uninsured patients routinely paid $300 or more per month for a single Lantus SoloSTAR pen box. The $35 figure now available in New Hampshire reflects both that list-price reduction and the availability of pharmacy-level discount tools like GoodRx and RxSaver, which aggregate pricing across chains such as CVS, Walgreens, Rite Aid, and Walmart.

Price varies by pharmacy. A 5-pen box of Lantus SoloSTAR (3 mL, 100 units/mL per pen) at a Walmart in Manchester may cost $32 with a GoodRx coupon, while the same box at a smaller independent pharmacy in Hanover might run $42. Patients should compare prices across at least three pharmacies before filling. Checking both chain and independent options matters, because negotiated discount rates differ by pharmacy buying group.

For patients on higher doses (above 40 units per day), monthly costs scale proportionally. A patient injecting 60 units nightly may need two boxes per month, pushing cash-pay costs to $70 or more even at discount pricing [2].

New Hampshire Medicaid Does Not Cover Lantus

New Hampshire Medicaid, administered through the NH Department of Health and Human Services, does not include Lantus on its preferred drug list as of 2026. This means Medicaid beneficiaries in the state cannot fill a Lantus prescription without a prior authorization, and even with PA, coverage is not guaranteed.

The state's Medicaid formulary instead favors NPH insulin (Humulin N, Novolin N) as the preferred basal insulin, along with select biosimilar insulin glargine products. Semglee (insulin glargine-yfgn) appears on some managed Medicaid plan formularies in New Hampshire as a non-preferred but accessible alternative.

Patients on New Hampshire Medicaid who need insulin glargine specifically should ask their prescriber to submit a prior authorization request citing medical necessity. According to the American Diabetes Association's Standards of Care, basal insulin analogs like glargine carry a lower hypoglycemia risk compared to NPH, which can support a medical necessity argument for patients with documented nocturnal hypoglycemia or erratic glucose control on NPH [3].

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has stated: "No person with diabetes should ever have to ration their insulin or go without due to cost. Formulary restrictions that limit access to modern insulin analogs can compromise glycemic control and patient safety" [4].

If prior authorization is denied, patients can appeal through the NH Medicaid fair hearing process or explore the compounded insulin glargine pathway described below.

Compounded Insulin Glargine Through 503A Pharmacies

Compounded insulin glargine is legal in New Hampshire when dispensed by a licensed 503A compounding pharmacy operating under a valid patient-specific prescription. This pathway can bring the out-of-pocket cost to $0 for qualifying patients, particularly through telehealth platforms that bundle the prescription, compounding, and shipping into a single service.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacies to compound medications, including insulin glargine, for individual patients when a prescriber determines that a commercially available product does not meet the patient's needs [5]. New Hampshire's Board of Pharmacy recognizes 503A compounding, and several compounding pharmacies both in-state and out-of-state (shipping into NH) offer insulin glargine preparations.

There are clinical considerations. Compounded insulin glargine is not FDA-approved and does not undergo the same batch-level testing as commercially manufactured Lantus or its biosimilars. The FDA has issued guidance noting that compounded drugs are not evaluated for safety, efficacy, or manufacturing quality in the same manner as approved drugs [6]. Patients choosing this route should verify that their compounding pharmacy holds current state licensure, follows USP 797 sterile compounding standards, and provides certificates of analysis for each batch.

For patients who are cost-constrained and cannot access Lantus through insurance or manufacturer programs, the compounded route offers a viable option. But it is not equivalent to FDA-approved insulin glargine from a regulatory standpoint.

Insurance Coverage for Lantus in New Hampshire

Commercial insurance plans in New Hampshire vary widely in how they cover Lantus. Most employer-sponsored plans and individual marketplace plans (purchased through healthcare.gov for NH residents) include insulin glargine on their formularies, though tier placement differs.

Tier 2 (preferred brand) placement typically means a copay of $25 to $50 per month. Tier 3 (non-preferred brand) placement can push copays to $75 to $150, or a coinsurance percentage of 25% to 40% of the negotiated price. Some plans have moved Lantus to Tier 1 following the list-price reduction.

New Hampshire passed Senate Bill 416 in 2020, which does not directly cap insulin copays but did establish an emergency insulin access program for state residents. The federal Inflation Reduction Act of 2022 caps insulin costs at $35 per month for Medicare Part D beneficiaries, but this cap does not apply to commercial plans in New Hampshire unless the plan voluntarily adopts it [7].

Patients with commercial insurance should:

1. Check their plan's formulary at the insurer's website or by calling the number on their insurance card
2. Ask whether Semglee or Rezvoglar (both insulin glargine biosimilars) sit on a lower tier than Lantus
3. Confirm whether their plan has voluntarily adopted a $35 insulin copay cap
4. Request a tier exception if Lantus is non-preferred but medically necessary

Anthem, Cigna, and Ambetter all operate individual and small-group plans in New Hampshire's marketplace. Coverage details change annually during open enrollment, so checking the current formulary before each plan year matters.

The Sanofi Insulins Valyou Savings Program

Sanofi's Insulins Valyou Savings Program caps the cost of Lantus at $35 per month for eligible patients. This program works in New Hampshire and does not require insurance. The card is available to U.S. residents with commercial insurance or no insurance at all.

How it works in practice: a patient presents the Valyou savings card (downloaded from Sanofi's insulin pricing website) at any participating New Hampshire pharmacy. The pharmacist processes the card as primary or secondary coverage. If the patient is uninsured, the card acts as the primary discount. If the patient has commercial insurance, the card can cover remaining copay costs after insurance processes the claim. The result is a maximum of $35 per 30-day supply.

Key restrictions apply. The Valyou card does not work with Medicare, Medicaid, TRICARE, or any other federal or state government-funded program. Patients on these programs are ineligible. The card is also limited to a maximum of 10 pens or 10 vials per fill, which covers standard dosing for most patients but may not suffice for high-dose regimens [1].

According to the ORIGIN trial (N=12,537), insulin glargine used over a median 6.2 years in patients with cardiovascular risk factors and dysglycemia showed a neutral effect on cardiovascular outcomes compared to standard care, with a modest increase in hypoglycemia but no increase in cancer incidence [8]. This long-term safety profile supports ongoing use of insulin glargine for patients who find an affordable access pathway. The trial's findings informed the ADA's recommendation of glargine as a first-line basal insulin option.

Biosimilar Alternatives Available in New Hampshire

Three FDA-approved insulin glargine biosimilars are available in New Hampshire pharmacies: Semglee (insulin glargine-yfgn, manufactured by Viatris), Rezvoglar (insulin glargine-aglr, Eli Lilly), and Basaglar (insulin glargine, Eli Lilly). These products are therapeutically equivalent to Lantus and typically cost less.

Semglee was the first interchangeable biosimilar insulin approved by the FDA in July 2021, meaning pharmacists in New Hampshire can substitute it for Lantus without contacting the prescriber, provided the prescription does not specify "dispense as written" [9]. This interchangeability designation is clinically significant. It means the FDA determined that Semglee produces the same clinical result as Lantus in any given patient, and that alternating between the two does not increase immunogenicity risk.

Cash-pay pricing for biosimilar insulin glargine in New Hampshire generally runs 15% to 40% below Lantus. With GoodRx or similar tools, Semglee may cost $25 to $30 per month at high-volume pharmacies. Basaglar, which is not rated as interchangeable (it was approved via the 505(b)(2) pathway, not the biosimilar pathway), typically prices slightly higher at $30 to $38 per month with coupons.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington and a leading voice in insulin access, has noted: "For the vast majority of patients on insulin glargine, switching between reference products and biosimilars produces no meaningful difference in glycemic control. The barriers are formulary design and patient awareness, not pharmacology" [10].

Patients filling biosimilar prescriptions should confirm the specific product with their pharmacist, because insulin pen devices differ between manufacturers and require product-specific training on injection technique and dose dialing.

Telehealth Prescribing for Lantus in New Hampshire

Telehealth prescribing of insulin glargine is legal in New Hampshire. The state's telemedicine laws, updated during and after the COVID-19 public health emergency, permit licensed prescribers to evaluate patients and prescribe medications, including insulin, via synchronous audio-video visits. New Hampshire does not require an in-person visit before initiating an insulin prescription via telehealth [11].

Several telehealth platforms serve New Hampshire patients seeking insulin glargine prescriptions. These platforms typically charge a consultation fee ($20 to $99) and can send the prescription to any New Hampshire pharmacy or, in some cases, to a partner 503A compounding pharmacy.

Patients using telehealth for insulin management should ensure:

1. The prescriber holds an active New Hampshire medical license (verifiable at the NH Board of Medicine website)
2. The platform provides ongoing follow-up, not just an initial prescription
3. Lab work (HbA1c, fasting glucose, renal function) is completed within the prior 90 days and shared with the telehealth provider
4. A plan exists for dose titration, because insulin glargine doses often require adjustment over the first 4 to 8 weeks

The ADA Standards of Care recommend HbA1c monitoring every 3 months for patients not at goal and every 6 months for those with stable glycemic control [3]. Telehealth visits can accommodate this follow-up schedule without requiring travel to an endocrinology office, which matters in rural parts of New Hampshire where specialist access is limited. Grafton, Coos, and Sullivan counties have fewer than one endocrinologist per 25,000 residents.

How to Get the Lowest Price on Lantus in New Hampshire

The cheapest pathway depends on your insurance status. Here is a decision framework ranked by typical out-of-pocket cost:

Uninsured, cost is the primary concern: Use the Sanofi Valyou card at a retail pharmacy ($35/month) or explore compounded insulin glargine through a 503A pharmacy ($0 in some programs). Compare both options, because the compounded product is not FDA-approved.

Commercially insured with high copay: Check whether your plan covers Semglee or Rezvoglar at a lower tier. If not, apply the Sanofi Valyou card as secondary coverage to reduce your copay. Request a tier exception from your insurer if Lantus is medically necessary.

Medicare Part D: The Inflation Reduction Act caps your insulin cost at $35/month regardless of which insulin glargine product your plan covers [7]. The Valyou card cannot be used with Medicare.

New Hampshire Medicaid: Request prior authorization for insulin glargine. If denied, ask about Semglee coverage or appeal through the fair hearing process. The compounded pathway is also available but requires a non-Medicaid prescription.

For all patients: Compare prices using GoodRx, RxSaver, or the Sanofi pricing tool before each fill. Prices change monthly at the pharmacy level, and a $5 to $10 difference between pharmacies is common across the state.

The combination of Sanofi's list-price cut, biosimilar competition, the Medicare $35 cap, and 503A compounding availability means that no New Hampshire resident should pay more than $35 per month for insulin glargine in 2026 if they know which programs to access.